Agios Pharmaceuticals (AGIO) Projected to Post Quarterly Earnings on Wednesday

Agios Pharmaceuticals (NASDAQ:AGIO) is projected to announce its Q1 2026 results before the market opens on Wednesday, April 29th. Analysts expect the company to announce earnings of ($1.82) per share and revenue of $13.9110 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 8:00 AM ET.

Agios Pharmaceuticals Stock Down 2.9%

Shares of NASDAQ AGIO opened at $26.29 on Wednesday. The company’s fifty day moving average is $30.12 and its 200-day moving average is $31.64. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -3.70 and a beta of 0.79. Agios Pharmaceuticals has a twelve month low of $22.24 and a twelve month high of $46.00.

More Agios Pharmaceuticals News

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Bank of America cut its price target from $44 to $41 but kept a “buy” rating, signaling continued analyst conviction in long?term upside despite the recent headwinds. Article Title
• Positive Sentiment: HC Wainwright lowered its target from $65 to $50 while maintaining a “buy” rating, indicating bullish analyst views remain albeit with reduced near?term expectations. Article Title
• Negative Sentiment: Coverage and analysis argue Novo’s late?stage win materially alters the PK?activator competitive landscape, a direct challenge to mitapivat’s market opportunity and approval outlook. Article Title
• Negative Sentiment: Market coverage reports that Agios shares plunged after Novo’s PKR activator met its endpoints in a sickle cell study, increasing investor concern about mitapivat’s competitiveness. Article Title
• Negative Sentiment: Newswire reports and analysis summarize Novo’s trial win and emphasize pressure on Agios from a surprise competitor success. Article Title
• Negative Sentiment: Industry coverage explains why Novo’s late?stage result is a material commercial threat to rivals and why the market punished Agios stock. Article Title
• Negative Sentiment: Consumer/business press pieces highlight the share?price drop and investor reaction after the surprise Novo data release. Article Title
• Negative Sentiment: Market writeups report a ?20–25% tumble after the Novo announcement, reflecting rapid repricing of Agios’s sickle?cell prospects. Article Title

Insider Transactions at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 3,262 shares of the company’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $113,224.02. Following the completion of the transaction, the insider directly owned 46,829 shares of the company’s stock, valued at approximately $1,625,434.59. This represents a 6.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sarah Gheuens sold 2,940 shares of the company’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total transaction of $102,047.40. Following the completion of the transaction, the insider directly owned 80,277 shares of the company’s stock, valued at approximately $2,786,414.67. The trade was a 3.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 15,582 shares of company stock worth $520,405. Company insiders own 4.93% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGIO. Wellington Management Group LLP increased its stake in Agios Pharmaceuticals by 485.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after buying an additional 2,049,287 shares during the last quarter. MPM Bioimpact LLC bought a new stake in Agios Pharmaceuticals during the 4th quarter worth about $35,478,000. State Street Corp lifted its position in Agios Pharmaceuticals by 37.4% during the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after buying an additional 845,433 shares in the last quarter. TCG Crossover Management LLC lifted its position in Agios Pharmaceuticals by 105.2% during the 3rd quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock worth $57,402,000 after buying an additional 733,038 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in Agios Pharmaceuticals during the 3rd quarter worth about $19,889,000.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on AGIO shares. Wall Street Zen raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. JPMorgan Chase & Co. lifted their price target on shares of Agios Pharmaceuticals from $31.00 to $36.00 and gave the stock a “neutral” rating in a research report on Monday, April 6th. Bank of America reduced their price target on shares of Agios Pharmaceuticals from $44.00 to $41.00 and set a “buy” rating on the stock in a research report on Tuesday. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Friday, March 27th. Finally, HC Wainwright reduced their price target on shares of Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday. Six analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $41.78.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.